Immunocore (NASDAQ:IMCR) Announces Earnings Results

Immunocore (NASDAQ:IMCR) posted its earnings results on Friday. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.10), FiscalAI reports. Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. The firm had revenue of $102.22 million during the quarter, compared to the consensus estimate of $152.20 million.

Immunocore Price Performance

Immunocore stock traded up $2.59 during trading hours on Friday, hitting $30.99. 1,526,513 shares of the company traded hands, compared to its average volume of 507,836. Immunocore has a 1-year low of $27.50 and a 1-year high of $40.71. The firm has a market cap of $1.60 billion, a P/E ratio of -83.75 and a beta of 0.82. The firm’s 50-day simple moving average is $31.64 and its two-hundred day simple moving average is $31.73. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on IMCR shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, October 15th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Morgan Stanley set a $43.00 target price on Immunocore in a research report on Friday, August 7th. Zacks Research downgraded Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.86.

Immunocore Company Profile

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.